奥曲肽治疗消化系内分泌肿瘤进展

utic considerations for malignant carcinoid syndr ome. Acta Oncol，1989；28(3)：433 　8　Yinik A, Binder M, Choil TK, et al. Treatment of the carcinoid syn drome with the somatostatin analogue. Dig Dis Sci，1989；34(1)：14 　9　Joensum H, Burroughs AK. Dramatic response of a metastatic careimo id tumor to a comibnation of interferon and octreotide. Acta Endocrinol Copenh，1992；126：184 　10　Glaser B, Rosler A, Halperin Y. Chronic treatment of a benign ins ulinoma using the longacting somatostatin analogue SMS 201-955. Isr J M ed Sci，1990；26(1)：16 　11　Verschoor L, Uitterlinden P, Lamberts SW, et al. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Chin Endocrinool，1986；25(5)：555 　12　Vance ML. Long-term treatment of 18 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med，1991；151：1573 　13　Eijeck CHJ. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg，1994；81(9)：1333 　14　Maton PN, Kussin P. The use of the long-acting somatostatin analo gue, octreotide acetate. in patients with islet cell tumors. Gastroente rol Clin North Am，1989；18：897 　15　Lorcy Y, Derennes V, Delanbre C, et al. Remission of recurrent Cu shing’s disease with an analog of somatostatin(letter). Presse Med，19 8 8；17：1217 　16　Zhu X F, Melmed S, Torres AJ, et al. Effect of small doses of som atostatin analog. octreotide, on gallbladder contractility in normal ch inese adults. Dig Dis Sci，1992；37(1)：105